AstraZeneca can inspect Pharmacor emails in fight over Forxiga patent

Intellectual Property 2026-04-10 11:54 pm By Andy Sidler Melbourne

AstraZeneca can inspect Pharmacor’s emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege.